XORTX Therapeutics Inc
XRTX0.560USD
-0.016-2.74%
收盤 12/24, 13:00（美東）報價延遲15分鐘
2.92M總市值
虧損本益比TTM
關於 XORTX Therapeutics Inc 公司
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
XORTX Therapeutics Inc簡介
公司代碼XRTX
公司名稱XORTX Therapeutics Inc
上市日期Sep 30, 2015
CEODavidoff (Allen W)
員工數量2
證券類型Ordinary Share
年結日Sep 30
公司地址3710 - 33rd Street NW
城市CALGARY
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編T2L 2M1
電話14034557727
網址https://www.xortx.com/
公司代碼XRTX
上市日期Sep 30, 2015
CEODavidoff (Allen W)
XORTX Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Ms. Abigail Jenkins
Ms. Abigail Jenkins
Independent Director
Independent Director
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
XTX Markets LLC
0.20%
Giovinazzo (Anthony)
0.14%
其他
88.47%
持股股東
持股股東
佔比
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
XTX Markets LLC
0.20%
Giovinazzo (Anthony)
0.14%
其他
88.47%
股東類型
持股股東
佔比
Corporation
8.22%
Individual Investor
1.87%
Hedge Fund
1.24%
Venture Capital
0.20%
其他
88.47%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
16
63.97K
1.23%
-645.66K
2025Q2
17
129.44K
3.30%
-739.58K
2025Q1
20
127.29K
3.49%
-606.22K
2024Q4
21
385.20K
10.34%
-244.07K
2024Q3
22
287.39K
12.35%
-145.77K
2024Q2
20
276.67K
12.12%
-141.93K
2024Q1
21
272.84K
13.24%
-121.02K
2023Q4
19
553.49K
27.69%
+481.09K
2023Q3
20
176.53K
8.83%
-185.14K
2023Q2
19
179.60K
8.98%
-178.94K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Davidoff, Allen Warren
120.45K
2.31%
+8.19K
+7.30%
Jul 22, 2025
Citadel Advisors LLC
38.47K
0.74%
+38.47K
--
Jun 30, 2025
Giovinazzo (Anthony)
9.63K
0.18%
--
--
Apr 30, 2025
RBC Dominion Securities, Inc.
--
0%
-1.49K
-100.00%
Mar 31, 2025
Van Damme (Paul Joseph)
7.11K
0.14%
--
--
Apr 30, 2025
Clearstead Advisors LLC
277.00
0.01%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
20.79K
0.4%
+20.79K
--
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
公告日期
類型
比率
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
常見問題
XORTX Therapeutics Inc的前五大股東是誰？
XORTX Therapeutics Inc的前五大股東如下：
Davidoff, Allen Warren持有股份：120.45K佔總股份比例：2.31%。
Citadel Advisors LLC持有股份：38.47K佔總股份比例：0.74%。
Giovinazzo (Anthony)持有股份：9.63K佔總股份比例：0.18%。
RBC Dominion Securities, Inc.持有股份：0.00佔總股份比例：0.00%。
Van Damme (Paul Joseph)持有股份：7.11K佔總股份比例：0.14%。
Davidoff, Allen Warren持有股份：120.45K佔總股份比例：2.31%。
Citadel Advisors LLC持有股份：38.47K佔總股份比例：0.74%。
Giovinazzo (Anthony)持有股份：9.63K佔總股份比例：0.18%。
RBC Dominion Securities, Inc.持有股份：0.00佔總股份比例：0.00%。
Van Damme (Paul Joseph)持有股份：7.11K佔總股份比例：0.14%。
XORTX Therapeutics Inc的前三大股東類型是什麼？
XORTX Therapeutics Inc 的前三大股東類型分別是：
Lincoln Alternative Strategies LLC
Davidoff, Allen Warren
Citadel Advisors LLC
Lincoln Alternative Strategies LLC
Davidoff, Allen Warren
Citadel Advisors LLC
有多少機構持有XORTX Therapeutics Inc(XRTX)的股份？
截至2025Q3，共有16家機構持有XORTX Therapeutics Inc的股份，合計持有的股份價值約為63.97K，占公司總股份的1.23% 。與2025Q2相比，機構持股有所增加，增幅為-2.08%。
哪個業務部門對XORTX Therapeutics Inc的收入貢獻最大？
在--，--業務部門對XORTX Therapeutics Inc的收入貢獻最大，創收--，占總收入的--% 。
